

Arnold S Freedman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6332819/publications.pdf>

Version: 2024-02-01

74
papers

4,316
citations

147801

31
h-index

110387

64
g-index

75
all docs

75
docs citations

75
times ranked

5361
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting constitutively active <sc>STAT3</sc> in chronic lymphocytic leukemia: A clinical trial of the <sc>STAT3</sc> inhibitor pyrimethamine with pharmacodynamic analyses. American Journal of Hematology, 2021, 96, E95-E98.	4.1	17
2	Follicular lymphoma: 2020 update on diagnosis and management. American Journal of Hematology, 2020, 95, 316-327.	4.1	140
3	Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Advances, 2020, 4, 858-867.	5.2	40
4	Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 22-23.	1.4	4
5	Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy. Blood, 2020, 136, 37-38.	1.4	1
6	Increased Risk of Infectious Complications in Older Patients With Indolent Non-Hodgkin Lymphoma Exposed to Bendamustine. Clinical Infectious Diseases, 2019, 68, 247-255.	5.8	42
7	PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood, 2019, 134, 22-29.	1.4	129
8	Follicular lymphoma: 2018 update on diagnosis and management. American Journal of Hematology, 2018, 93, 296-305.	4.1	87
9	Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Phase 2 Clinical Trials and Off-Trial Experience. Blood, 2018, 132, 145-145.	1.4	5
10	PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation. Blood, 2018, 132, 1650-1650.	1.4	2
11	PD-1 Blockade for Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation. Blood, 2018, 132, 706-706.	1.4	3
12	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. Journal of Clinical Oncology, 2017, 35, 1598-1605.	1.6	339
13	Infectious Complications Associated with Bendamustine Exposure in Patients with Indolent non-Hodgkin Lymphoma. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
14	Persistence of dysphagia and odynophagia after mediastinal radiation and chemotherapy in patients with lung cancer or lymphoma. Ecological Management and Restoration, 2016, 30, 1-8.	0.4	1
15	Is There a Best Initial Treatment for a New Patient With Low Grade Follicular Lymphoma. Current Hematologic Malignancy Reports, 2016, 11, 218-223.	2.3	0
16	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell, 2016, 29, 574-586.	16.8	227
17	Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood, 2016, 128, 195-203.	1.4	259
18	A phase 2 study of Rituximab+ Bendamustine and Rituximab+ Cytarabine for transplant-eligible patients with mantle cell lymphoma. British Journal of Haematology, 2016, 173, 89-95.	2.5	51

#	ARTICLE	IF	CITATIONS
19	Follicular lymphoma: 2015 update on diagnosis and management. American Journal of Hematology, 2015, 90, 1171-1178.	4.1	28
20	Rethinking Prognosis and Therapy for Follicular Lymphoma. Journal of Clinical Oncology, 2015, 33, 2489-2491.	1.6	2
21	Sequencing-Based Detection of Circulating Tumor DNA in the Autologous Stem Cell Grafts of Patients with Diffuse Large B-Cell Lymphoma Undergoing Hematopoietic Stem Cell Transplantation. Blood, 2015, 126, 3156-3156.	1.4	2
22	Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation. Blood, 2015, 126, 522-522.	1.4	3
23	B and T-Cell Lymphoma Patient-Derived Xenografts Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development. Blood, 2015, 126, 4001-4001.	1.4	0
24	Follicular lymphoma: 2014 update on diagnosis and management. American Journal of Hematology, 2014, 89, 429-436.	4.1	54
25	Phase I/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. British Journal of Haematology, 2014, 164, 258-265.	2.5	65
26	Early lymphoid lesions: conceptual, diagnostic and clinical challenges. Haematologica, 2014, 99, 1421-1432.	3.5	50
27	Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma. Journal of Clinical Oncology, 2014, 32, 1797-1803.	1.6	75
28	Low-Dose Involved-Field Radiation in the Treatment of Non-Hodgkin Lymphoma: Predictors of Response and Treatment Failure. International Journal of Radiation Oncology Biology Physics, 2013, 86, 121-127.	0.8	49
29	Follicular lymphoma: 2012 update on diagnosis and management. American Journal of Hematology, 2012, 87, 988-995.	4.1	38
30	Risk Alleles Identified in Genome-Wide Association Studies Are Associated with Expression Quantitative Trait Loci in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 2875-2875.	1.4	1
31	Prognostic Factors for Patients with Diffuse Large B Cell Lymphoma and Transformed Indolent Lymphoma Undergoing Autologous Stem Cell Transplantation in the PET Era. Blood, 2012, 120, 1980-1980.	1.4	0
32	Somatic and Germline Copy Neutral Loss of Heterozygosity Are Common in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 4567-4567.	1.4	0
33	Follicular lymphoma: 2011 update on diagnosis and management. American Journal of Hematology, 2011, 86, 768-775.	4.1	33
34	Everolimus in Combination with Rituximab Induces Complete Responses in Heavily Pretreated Diffuse Large B-Cell Lymphoma. Blood, 2011, 118, 1635-1635.	1.4	3
35	Obatoclox in Combination with Fludarabine and Rituximab (FR) Is Well-Tolerated and Shows Promising Clinical Activity in Relapsed CLL/SLL. Blood, 2011, 118, 2865-2865.	1.4	3
36	Novel Germline Genetic Variants Associated with Familial Chronic Lymphocytic Leukemia (CLL). Blood, 2011, 118, 465-465.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Down-Regulation of CD9 Expression and its Correlation to Tumor Progression in B Lymphomas. American Journal of Pathology, 2010, 177, 377-386.	3.8	16
38	Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular Lymphoma. Journal of Clinical Oncology, 2009, 27, 3036-3043.	1.6	132
39	Reply to J. Mehta. Journal of Clinical Oncology, 2009, 27, e139-e140.	1.6	0
40	Phase II study of a TLR α 9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. British Journal of Haematology, 2009, 146, 282-291.	2.5	75
41	Targeting the follicular lymphoma microenvironment through blockade of TNF α with etanercept. Leukemia and Lymphoma, 2008, 49, 902-909.	1.3	11
42	Myeloablative Therapy With Autologous Bone Marrow Transplantation for Follicular Lymphoma at the Time of Second or Subsequent Remission: Long-Term Follow-Up. Journal of Clinical Oncology, 2007, 25, 2554-2559.	1.6	219
43	A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas.. Blood, 2007, 110, 1358-1358.	1.4	2
44	Prospective Evaluation of FDG-PET Imaging of Treatment Response in Relapsed Follicular Lymphoma.. Blood, 2007, 110, 2331-2331.	1.4	6
45	Non-Myeloablative Allogeneic Transplantation for Hodgkin α ™s and Non-Hodgkin α ™s Lymphoma: Evidence for a Graft-Versus-Lymphoma Effect and Relevance of Chimerism.. Blood, 2007, 110, 3041-3041.	1.4	0
46	Non α ™ Transplant-Related Treatment Options in Follicular Lymphoma. Biology of Blood and Marrow Transplantation, 2006, 12, 53-58.	2.0	1
47	Phase III Trial of Active Immunotherapy (Favid α ™, Id/KLH) Following Rituximab Induction Therapy: Clinical Responses in Patients (pts) with Follicular Non-Hodgkin α ™s Lymphoma (fNHL).. Blood, 2006, 108, 2756-2756.	1.4	5
48	Long-Term Follow-Up of Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission: Bone Marrow Involvement at Harvest and PCR Detectable Disease after Ex Vivo Purging Predict Relapse.. Blood, 2006, 108, 3041-3041.	1.4	0
49	Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon- β / γ -inducible gene expression, without significant toxicity. Blood, 2005, 105, 489-495.	1.4	155
50	Biology and Management of Histologic Transformation of Indolent Lymphoma. Hematology American Society of Hematology Education Program, 2005, 2005, 314-320.	2.5	31
51	Follicular lymphoma with bilateral testicular and epididymal involvement: Case report and review of the literature. Leukemia and Lymphoma, 2005, 46, 1663-1666.	1.3	4
52	Autologous Bone Marrow Transplantation for Marginal Zone Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 2004, 45, 315-320.	1.3	15
53	B-cell purging in autologous stem-cell transplantation for non-Hodgkin lymphoma. Lancet Oncology, The, 2004, 5, 711-717.	10.7	20
54	Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission: Long Term Follow up of Two Sequential Trials with Standard Dose and High Dose CHOP Induction.. Blood, 2004, 104, 5243-5243.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Multicolour fluorescence <i>in situ</i> hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcome. <i>British Journal of Haematology</i> , 2003, 122, 745-759.	2.5	39
56	Effective purging of autologous hematopoietic stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patients with non-Hodgkin's lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 429-434.	2.0	11
57	Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2002, 117, 828-834.	2.5	131
58	CXCL13 (BCA-1) is produced by follicular lymphoma cells: role in the accumulation of malignant B cells. <i>British Journal of Haematology</i> , 2002, 119, 492-495.	2.5	65
59	MCP-1 modulates chemotaxis by follicular lymphoma cells. <i>British Journal of Haematology</i> , 2001, 115, 554-562.	2.5	31
60	Functional Effects of TNF and Lymphotoxin β_2 on FDC-like Cells. <i>Cellular Immunology</i> , 2000, 203, 134-143.	3.0	45
61	Outcome in Patients With Myelodysplastic Syndrome After Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 3128-3135.	1.6	180
62	Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular Lymphoma. <i>Blood</i> , 1999, 94, 3325-3333.	1.4	319
63	Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 1999, 5, 262-268.	2.0	68
64	High Dose Therapy and Autologous Stem Cell Transplantation in Follicular non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 1998, 28, 219-230.	1.3	18
65	Unbalanced Expression of Bcl-2 Family Proteins in Follicular Lymphoma: Contribution of CD40 Signaling in Promoting Survival. <i>Blood</i> , 1998, 91, 244-251.	1.4	114
66	Association of the Cas-like Molecule HEF1 with CrkL Following Integrin and Antigen Receptor Signaling in Human B-Cells: Potential Relevance to Neoplastic Lymphohematopoietic Cells. <i>Leukemia and Lymphoma</i> , 1997, 28, 65-72.	1.3	40
67	Monoclonal Antibody-Purged Bone Marrow Transplantation Therapy for Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 1995, 17, 87-93.	1.3	32
68	Expression of Vascular Cell Adhesion Molecule-1 by Follicular Dendritic Cells. <i>Leukemia and Lymphoma</i> , 1995, 18, 259-264.	1.3	8
69	Adhesion of Follicular Lymphoma Cells to Lymphoid Germinal Centers—A Potential Mechanism of Tumor Cell Homing Following Autologous Transplantation. <i>Leukemia and Lymphoma</i> , 1994, 13, 47-52.	1.3	13
70	B-Cell Monoclonal Antibodies and Their Use in Clinical Oncology. <i>Cancer Investigation</i> , 1991, 9, 69-84.	1.3	3
71	Immunologic Purging of Marrow Assessed by PCR before Autologous Bone Marrow Transplantation for B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 1991, 325, 1525-1533.	27.0	678
72	The Relationship of Chronic Lymphocytic Leukemia to Normal Activated B Cells. <i>Leukemia and Lymphoma</i> , 1990, 1, 293-300.	1.3	7

#	ARTICLE	IF	CITATIONS
73	Expression and regulation of CD5 on in vitro activated human B cells. European Journal of Immunology, 1989, 19, 849-855.	2.9	64
74	Autologous bone marrow transplantation therapy for multiple myeloma. European Journal of Haematology, 1989, 43, 157-163.	2.2	5